In a significant development, a GOP-led U.S. House health subcommittee this afternoon voted 16 to 12 along party lines to pass and send to the full committee legislation to impose significant new reporting requirements on 340B disproportionate share hospitals.
The
…
The U.S. House Energy & Commerce health subcommittee tomorrow will markup a bill by Vice Chair Larry Bucshon (R-Ind.) to impose significant annual reporting requirements on 340B disproportionate share hospitals “and any other covered entity” that the U.S. Secretary of
…
Correspondence in April and May 2020 between the 340B prime vendor and a law firm sheds more light on the start of a policy that the federal government ended abruptly last week that let hospitals start using 340B drugs at
…
Drug manufacturer Sanofi late yesterday afternoon toughened its policy on 340B pricing involving the use of contract pharmacies. Its announcement came about two hours after Merck made a similar move.
Sanofi’s original policy applied to disproportionate share hospitals, rural
…
Drug manufacturer Merck today stiffened its conditions on 340B pricing when hospitals and community health centers use contract pharmacies to dispense most Merck drugs to patients.
Merck told covered entities about the changes in a letter delivered by email
…
The U.S. Health Resources and Services Administration midday yesterday and the 340B prime vendor Apexus this morning, in connection with the end of the COVID-19 public health emergency late last night, withdrew mostly identical 340B program FAQs about use of
…
U.S. Sen. Mike Braun (R-Ind.) did not seek to amend a PBM oversight bill that is being marked up today to require 340B hospitals and possibly other covered entities to be more transparent about how they use money saved or
…
A Louisiana Senate health committee yesterday passed a bill that will stop drug manufacturer interference with 340B contract pharmacy arrangements, rejecting an amendment that would have stripped the language from the measure.
HB 548, which also would prohibit pharmacy benefit
…
Drug manufacturer Janssen Pharmaceuticals said last week it would pay refunds for overcharges on 340B drugs purchased in the second quarter of 2020, including top-selling psoriasis drug Stelara.
Janssen, part of Johnson & Johnson, said it owes or may owe
…
Q: Where did you grow up?
Ho Chi Minh City, Vietnam
Q: Where did you go to college/graduate school?
Northeastern University for Pharmacy and Columbia University for
…*Sign up for news summaries and alerts from 340B Report
